PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
Soligenix has recently achieved success in its first Phase 3 clinical trial of HyBryte™ (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer.
- Soligenix has recently achieved success in its first Phase 3 clinical trial of HyBryte™ (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer.
- The trial showed statistical significance in its primary endpoint, and a second confirmatory Phase 3 study is set to commence in 2024.
- The open-label study, involving nine patients, showed significant improvements in CTCL lesions, confirming the efficacy seen in the Phase 3 FLASH trial.
- "We will be enrolling the first patients in our 18-week Phase 3 placebo-controlled study evaluating HyBryte™ in CTCL across the US and Europe.